Kistefos
Kistefos is a privately owned investment firm based in Oslo, Norway, focusing on direct investments and fund of funds. It targets opportunities in offshore, shipping, banking and financial services, real estate, information technology, telecommunications, and related sectors, with involvement across Europe. The firm pursues early-stage, build-ups, growth capital, rescue financings, and buyouts, typically committing at least NOK 10 million per investment and aiming to acquire significant ownership. It seeks to be an active partner, often taking board seats, and supports portfolio companies through value creation initiatives. Investments are generally exited within three to seven years via public offerings or sales to trade buyers. The company operates with a flexible mandate to back companies at various life-cycle stages and geographies, and also employs a strategy of leveraging fund investments alongside direct deals. Kistefos was founded in 1989 and is based in Oslo.
Past deals in Oslo
Kappa Bioscience
Venture Round in 2009
Kappa Bioscience, based in Oslo, Norway, develops and produces vitamin K2 as menaquinone-7 for the food supplement and fortified foods markets. It markets a synthetic all-trans MK-7 under the K2VITAL brand and uses the DELTA microencapsulation technology to enhance stability in mineral formulations. The company supplies manufacturers of dietary supplements and fortified foods worldwide through a global distributor network. Founded in 2006, Kappa Bioscience emphasizes high-purity ingredients and reliable supply chains to support health-focused applications in bone and cardiovascular health.
Promon
Venture Round in 2008
Promon AS is a cybersecurity company based in Oslo, Norway, that specializes in developing and selling security software for businesses that handle sensitive information. Founded in 2006, Promon provides a suite of application security solutions designed to protect online services and software applications from security threats. Its products are aimed at online service providers, covering areas such as online banking, e-commerce, and enterprise resource planning systems. Promon's security technology extends beyond the application itself, proactively detecting and blocking potential threats to prevent data tampering and leakage. Through its integrated service protection and application protection offerings, Promon ensures the integrity and confidentiality of sensitive information for its clients.
OstomyCure
Venture Round in 2007
OstomyCure AS is a Medical Technology company with a headquarter in Oslo, Norway. The company develops a revolutionary technology called Transcutaneous Implant Evacuation System, The TIES® System.
The TIES® Continent Ileostomy System, is a titanium implant solution with a lid intended to replace a conventional ileostomy. It allows a more carefree life for patients who suffer from inflammatory bowel diseases such as Crohn´s disease, Ulcerative colitis, multiple cancer or other related diseases that need the removal of the colon (large intestine).
The TIES® System is the result of several years of research combined with the latest 3D manufacturing technology, developed and produced in accordance with regulatory standards to ensure safety for the patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.